

# Erkka SyvÄälahti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10394603/publications.pdf>

Version: 2024-02-01

33  
papers

2,139  
citations

331670

21  
h-index

434195

31  
g-index

33  
all docs

33  
docs citations

33  
times ranked

2598  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic D1-receptor blockade: effects on D2-receptor agonist-induced yawning in rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 43, 278-279.	2.4	2
2	The effects of lorazepam on extrastriatal dopamine D2/3-receptorsâ€”A double-blind randomized placebo-controlled PET study. <i>Psychiatry Research - Neuroimaging</i> , 2009, 174, 130-137.	1.8	9
3	The A1 allele of the human D2 dopamine receptor gene is associated with increased activity of striatal L-amino acid decarboxylase in healthy subjects. <i>Pharmacogenetics and Genomics</i> , 2005, 15, 387-391.	1.5	139
4	Cortical glutamateâ€”dopamine interaction and ketamine-induced psychotic symptoms in man. <i>Psychopharmacology</i> , 2005, 182, 375-383.	3.1	81
5	The amygdala and schizophrenia: a volumetric magnetic resonance imaging study in first-episode, neuroleptic-naive patients. <i>Biological Psychiatry</i> , 2003, 54, 1302-1304.	1.3	76
6	Personality Traits and Striatal Dopamine Synthesis Capacity in Healthy Subjects. <i>American Journal of Psychiatry</i> , 2003, 160, 904-910.	7.2	104
7	A volumetric MRI study of the entorhinal cortex in first episode neuroleptic-naive schizophrenia. <i>Biological Psychiatry</i> , 2002, 51, 1005-1007.	1.3	71
8	Sex differences in striatal presynaptic dopamine synthesis capacity in healthy subjects. <i>Biological Psychiatry</i> , 2002, 52, 759-763.	1.3	181
9	Ketamine does not decrease striatal dopamine D 2 receptor binding in man. <i>Psychopharmacology</i> , 2002, 164, 401-406.	3.1	65
10	Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. <i>Schizophrenia Research</i> , 2001, 52, 115-120.	2.0	102
11	The effects of amitriptyline, citalopram and reboxetine on autonomic nervous system. <i>Psychopharmacology</i> , 2001, 154, 343-349.	3.1	40
12	Sertindole is a serotonin 5-HT 2c inverse agonist and decreases agonist but not antagonist binding to 5-HT 2c receptors after chronic treatment. <i>Psychopharmacology</i> , 2001, 157, 180-187.	3.1	30
13	Lack of association between the functional variant of the catechol-o-methyltransferase (COMT) gene and early-onset alcoholism associated with severe antisocial behavior. <i>American Journal of Medical Genetics Part A</i> , 2000, 96, 348-352.	2.4	60
14	Measurement of extrastriatal D2-like receptor binding with [11C]FLB 457 â€” a test-retest analysis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000, 27, 1666-1673.	6.4	50
15	Brain 5-HT 2A receptor occupancy of deramciclanc in humans after a single oral administration - a positron emission tomography study. <i>Psychopharmacology</i> , 1999, 145, 76-81.	3.1	10
16	Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. <i>Schizophrenia Research</i> , 1999, 35, 41-50.	2.0	239
17	Effect of smoking on neuroleptics in schizophrenia. <i>Schizophrenia Research</i> , 1997, 23, 55-60.	2.0	64
18	Antagonist Binding Characteristics of the Ser311â†’Cys Variant of Human Dopamine D2Receptorin Vivoandin Vitro. <i>Biochemical and Biophysical Research Communications</i> , 1997, 232, 143-146.	2.1	13

#	ARTICLE	IF	CITATIONS
19	Effects of lorazepam administration on striatal dopamine D <sub>2</sub> receptor binding characteristics in man - a positron emission tomography study. <i>Psychopharmacology</i> , 1997, 132, 361-365.	3.1	16
20	Receptor binding profile and anxiolytic-type activity of deramciclone (EGIS-3886) in animal models. <i>Drug Development Research</i> , 1997, 40, 333-348.	2.9	34
21	Effects of clozapine metabolites and chronic clozapine treatment on rat brain GABA <sub>A</sub> receptors. <i>European Journal of Pharmacology</i> , 1996, 314, 319-323.	3.5	14
22	Integrated Treatment Model for First-Contact Patients with a Schizophrenia-Type Psychosis: The Finnish API Project. <i>Nordic Journal of Psychiatry</i> , 1996, 50, 281-287.	1.3	34
23	Dopamine in Schizophrenia. <i>Annals of Medicine</i> , 1996, 28, 557-561.	3.8	51
24	Striatal D <sub>2</sub> dopamine receptor binding characteristics in vivo in patients with alcohol dependence. <i>Psychopharmacology</i> , 1994, 116, 285-290.	3.1	235
25	Regulation of serotonin 5-HT <sub>2C</sub> receptors in the rat choroid plexus after acute clozapine treatment. <i>European Journal of Pharmacology</i> , 1994, 269, 201-208.	2.6	9
26	5-HT <sub>1C</sub> receptor-mediated phosphoinositide hydrolysis in the rat choroid plexus after chronic treatment with clozapine. <i>European Journal of Pharmacology</i> , 1994, 255, 91-97.	3.5	17
27	Decrease in Human Striatal Dopamine D <sub>2</sub> Receptor Density with Age: A PET Study with [ <sup>11</sup> C]Raclopride. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 1993, 13, 310-314.	4.3	186
28	Clozapine and N-desmethylozapine are potent 5-HT <sub>1C</sub> receptor antagonists. <i>European Journal of Pharmacology</i> , 1993, 245, 179-182.	2.6	121
29	Citalopram, a specific inhibitor of serotonin reuptake in treatment of psychotic and borderline patients. <i>Nordic Journal of Psychiatry</i> , 1992, 46, 181-187.	1.3	6
30	Chronic clozapine treatment down-regulates serotonin 5-HT <sub>1c</sub> receptors in rat brain. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1992, 16, 727-732.	4.8	23
31	Ethanol administration does not alter dopamine D <sub>1</sub> and D <sub>2</sub> receptor characteristics in rat brain. <i>Neuroscience Letters</i> , 1990, 108, 289-294.	2.1	39
32	Differential tolerance to cataleptic effects of SCH 23390 and haloperidol after repeated administration. <i>Psychopharmacology</i> , 1989, 98, 472-475.	3.1	18
33	Effects of the atypical antidopaminergic drug, metoclopramide and the selective antimuscarinic drug, pirenzepine on neurotransmission. <i>Nordic Journal of Psychiatry</i> , 1987, 41, 491-495.	0.1	0